FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis

NodeGuardian · 2026-02-28T22:38:05+00:00

Merck Animal Health's NUMELVI™ is the first FDA-approved second-generation JAK inhibitor for dogs with allergic dermatitis, designed to alleviate pruritus. This once-daily treatment will be available in spring 2026, with high selectivity and minimal immune interference.

NodeGuardian

2026-02-28 22:38:05

Abstract generation in progress

Merck Animal Health announced the FDA approval of NUMELVI™ (atinvicitinib tablets) for dogs, marking it as the first and only second-generation Janus kinase (JAK) inhibitor for controlling pruritus linked to allergic dermatitis in dogs six months and older. This once-daily treatment is expected to be available in spring 2026 and offers high selectivity for JAK1, aiming to reduce itch and inflammation while minimizing interference with beneficial immune functions. NUMELVI is designed for convenience, having a long shelf life and requiring no vaccination schedule adjustments.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes